Codexis Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
2.4 -0.41
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
2.4
Max
2.42
Pajamos | -18M -8.7M |
|---|---|
Pardavimai | -24M 15M |
Pelnas, tenkantis vienai akcijai | -0.1 |
Pelno marža | -57.083 |
Darbuotojai | 146 |
EBITDA | -23M -5.8M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +187.5% upside |
Kitas uždarbis | 2026-08-12 |
|---|
Rinkos kapitalizacija | 8.6M 237M |
|---|---|
Ankstesnė atidarymo kaina | 2.81 |
Ankstesnė uždarymo kaina | 2.4 |
Naujienos nuotaikos
By Acuity
23%
77%
48 / 342 reitingas Healthcare
Codexis Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
